Related Experiment Videos
[Relationship between ERCC1 expression and efficacy of neoadjuvant chemotherapy in the patients with non-small-cell
Songwen Zhou1, Caicun Zhou, Qinghua Xu
1Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433.
Background:
It has been proven that ERCC1(excision repair cross-complementation group 1)plays an important role in tumor sensitivity to platinum-based chemotherapy.This study was to examine the relationship between ERCC1 expression in NSCLCand efficacy of neoadjuvant chemotherapy.
Methods:
Expression levels of ERCC1 in 73 resected patients with NSCLC were detected with the method of immunohistochemistry. Expression differents of ERCC1 and its relationship with neoadjuvant chemotherapy were analysed with chi-square test, Log-rank test and Cox regression model risk.
Results:
The positive rate of ERCC1 in NSCLC was 34.25%. Expression rate for ERCC1 in NSCLC treated with neoadjuvant chemotherapy was significantly higher than in those without neoadjuvant group (48.48% vs 20.45%, P =0.025). Compared with the patients with ERCC1-negative tumors, the response rate in the patients with ERCC1-positive tumors was 31.3% vs 58.8%(Chi-Square=2.528,P =0.112), median survival time was 36 months vs 54 months (P =0.118), The 3-year overall survival rate were 43.8% vs 47.1%(Chi-Square=0.029,P =0.866)and The 5-year overall survival rate were 18.8% vs 23.5%(Chi-Square=0.414,P =0.520). COX multivariate regression analysis showed that disease stages, ERCC1 expression and neoadjuvant chemotherapy were independent prognostic facts in the patients.
Conclusions:
The expression level of ERCC1 is related to the prognosis in patients with NSCLC with neoadjuvant CT. Neoadjuvant CT can induce ERCC1 gene.
